Evidence map›Paper›PMID 40676250›Full record

ArticleCellular and molecular life sciences : CMLS2025

LRRK2 kinase modulates glucose-stimulated insulin secretion via RAB8 phosphorylation and ciliogenesis.

Nevia Dule, Algerta Marku, Alessandra Galli, Francesca Pischedda, Adriano Lama, Michela Castagna, Paola Marciani, Federico Bertuzzi, Giovanni Piccoli, Carla Perego

Abstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nevia Dule *Laboratory of Molecular and Cellular Physiology, Department of Excellence of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Via Trentacoste 2, 20134, Milan, Italy.
Algerta Marku *Laboratory of Molecular and Cellular Physiology, Department of Excellence of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Via Trentacoste 2, 20134, Milan, Italy.
Alessandra GalliLaboratory of Molecular and Cellular Physiology, Department of Excellence of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Via Trentacoste 2, 20134, Milan, Italy.
Francesca PischeddaCIBIO, Università Degli Studi di Trento, Dulbecco Telethon Institute, Trento, Italy.
Adriano LamaCIBIO, Università Degli Studi di Trento, Dulbecco Telethon Institute, Trento, Italy.
Michela CastagnaLaboratory of Molecular and Cellular Physiology, Department of Excellence of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Via Trentacoste 2, 20134, Milan, Italy.
Paola MarcianiLaboratory of Molecular and Cellular Physiology, Department of Excellence of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Via Trentacoste 2, 20134, Milan, Italy.
Federico BertuzziNiguarda Cà Granda Hospital, Milan, Italy.
Giovanni PiccoliCIBIO, Università Degli Studi di Trento, Dulbecco Telethon Institute, Trento, Italy.
Carla PeregoLaboratory of Molecular and Cellular Physiology, Department of Excellence of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Via Trentacoste 2, 20134, Milan, Italy. carla.perego@unimi.it.ORCID http://orcid.org/0000-0003-3027-1779

Funding

MIUR Department of Excellence, 2023-2027Piano di Sostegno per la Ricerca, Universita` degli Studi di Milano, Piano di Sostegno per la Ricerca, Universita` degli Studi di Milano,Progetti di rilevante interesse nazionale 20222LRHCWProgetti di rilevante interesse nazionale 20228XHTBZ
6 · The paper itself

Abstract

Leucine-rich repeat kinase 2 (LRRK2) encodes a multidomain protein whose mutations have been identified as genetic risk factors for Parkinson's disease (PD), an age-related neurodegenerative disorder. Outside the nervous system, LRRK2 is expressed in multiple tissues, including the endocrine pancreas, but its role here is unknown. Using pharmacological and molecular approaches, we show that LRRK2 kinase activity regulates stimulated insulin secretion by influencing secretory granule trafficking. The PD-associated LRRK2 mutant G2019S, characterized by enhanced kinase activity, increases the basal insulin release in complementary in vitro models and affects the metabolic profile in transgenic mice. Mechanistically, we demonstrate that LRRK2 kinase activity influences the formation of the primary cilium, an antenna-like structure acting as signaling platform to regulate hormones secretion. Specifically, LRRK2 phosphorylates RAB8 in a glucose-dependent manner, facilitating its recruitment to the primary cilium. These findings identify LRRK2 as a regulator of insulin secretion in pancreatic β-cells. Given the role of insulin signaling and glucose homeostasis in the nervous system, our data suggest that LRRK2 may also contribute to PD development through peripheral action.

Indexed as

CiliaGlucoseInsulinInsulin SecretionLeucine-Rich Repeat Serine-Threonine Protein Kinase-2rab GTP-Binding ProteinsAnimalsHEK293 CellsHumansInsulin-Secreting CellsMiceMice, Inbred C57BLMice, TransgenicMutationParkinson DiseasePhosphorylationGlucoseInsulinLeucine-Rich Repeat Serine-Threonine Protein Kinase-2Lrrk2 protein, mouseRab8 protein, mouserab GTP-Binding ProteinsInsulinLRRK2; β-cell; RABsParkinson diseasePrimary cilium

Identifiers

PMID40676250
PMCPMC12270992

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.